Clinical Trial

Trial Protocol ID USOR 24073_64007957MMY3006_MajesTEC-9

Trial Description

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Vinni Juneja, MD

Disease Types

Sponsor

  • Janssen

ClinicalTrials.gov NCT ID

  • NCT05572515